Earnings Call · Q4 FY2024·2024-11-26

Q4 24EPS -48.59%·Rev n/aQ3 24EPS -100.00%*·Rev n/aQ2 24EPS -100.00%*·Rev n/aQ1 24EPS -49.40%·Rev n/a⚠ consensus missing

ARROWHEAD PHARMACEUTICALS, INC. ARWR

Vince Anzalone — Likely a senior management or investor relations (handing over call)

Chris Anzalone — President and CEO

Bruce Given — Interim Chief Medical Officer

Andy Davis — Management, likely in clinical or medical affairs

James Hamilton — Management, likely Head of Research or Development

Ken Myszkowski — Management, likely CFO or Finance Executive

+24.2%1d on move date+24.5% vs SPY3d+25.1%5d+9.8%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARWR calls or request research access.

More ARWR calls Browse calls Request research access